Characterization of the Toll-like Receptor Expression Profile in Human Multiple Myeloma Cells

Jahangir Abdi¹, Tuna Mutis², Johan Garssen¹, Frank Redegeld¹

¹ Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands, ² Department of Clinical Chemistry & Hematology, University Medical Center Utrecht, Utrecht, The Netherlands

Abstract

Expression and function of Toll-like receptors (TLRs) in multiple myeloma (MM) has recently become the focus of several studies. Knowledge of expression and biology of these receptors in MM will provide us with a new insight into the role of an inflammatory environment in disease progression or pathogenesis of MM. However, to date a quite heterogeneous expression pattern of TLRs in MM particularly at gene level has been described while information on the TLR expression at the protein level is largely unavailable. In this study, we investigated the TLR expression in human myeloma cell lines (HMCLs) Fravel, L363, UM6, UM9, OPM1, OPM2, U266, RPMI 8226, XG1, and NCI H929 and primary cells from MM patients at both mRNA and protein level (western blot and flow cytometry). We found that all cell lines and primary cells expressed TLR1, TLR3, TLR4, TLR7, TLR8, and TLR9 mRNA and protein. TLR2 and TLR5 were expressed by the majority of HMCLs at mRNA but were not detectable at protein level, while primary samples showed a low level of TLR2, TLR3 and TLR5 protein expression. Our results indicate that MM cells express a broad range of TLRs with a degree of disparity between gene and protein expression pattern. The clear expression of TLRs in MM cells indicates a propensity for responding to tumor-induced inflammatory signals, which seem inevitable in the MM bone marrow environment.

Citation: Abdi J, Mutis T, Garssen J, Redegeld F (2013) Characterization of the Toll-like Receptor Expression Profile in Human Multiple Myeloma Cells. PLoS ONE 8(4): e60671. doi:10.1371/journal.pone.0060671

Materials and Methods

Reagents and Antibodies

All the antibodies used in this study for TLR detection were from IMGENEX (San Diego, CA, USA): TLR1 (IMG-5012), TLR2 (IMG-416A), TLR3 (IMG-315A), TLR4 (IMG-5031A), TLR5 (IMG-663A), TLR7 (IMG-581A), TLR8 (IMG-321A) and TLR9 (IMG-305E). The following secondary antibodies and isotype controls were used in the FACS experiments: F/ab’ anti-rabbit IgG-FITC, anti-mouse IgG-FITC, mouse IgG2b, κ, all from eBioscience, mouse IgG2a, κ from Biolegend (San Diego, CA, USA) and rabbit normal immunoglobulin from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-beta actin and the following secondary antibodies used for blotting experiments were from Santa Cruz Biotechnology: horseradish peroxidase-conjugated goat anti-mouse IgG and goat anti-rabbit IgG. HRP-conjugated goat anti-rabbit immunoglobulin was from DAKO (DK-2600 Glostrup, Denmark). Monoclonal anti-human CD138-APC was from Biolegend. All PCR and cDNA synthesis reagents including Platinum® Taq DNA polymerase were from Invitrogen.
Cells and Cell Culture

Human multiple myeloma cell lines, Fravel, L363, OPM-1, OPM-2, U266, RPMI-8226, XG1 and NCI-H929 were obtained from American Type Culture Collection (Manassas, VA, USA). UM-6 and UM-9 had been established by the Department of Clinical Chemistry & Hematology, University Medical Center Utrecht, Utrecht, the Netherlands [16,17]. All the cell lines were maintained in RPMI-1640 culture medium containing 2-mM L-glutamine supplemented with 5 or 10% fetal bovine serum and intermittently with antibiotics, in a 37°C incubator with 5% CO2.

XG1 and UM6 cell lines were cultured with 1 ng/mL and 5 ng/mL of recombinant human IL-6 (from eBioscience, San Diego, CA, USA), respectively. NCI-H929 cell line was cultured in the presence of 1 mM sodium pyruvate and 50 μM 2-mercaptoethanol. The cell cultures were within five to ten passages after thawing for the expression experiments.

Bone marrow mononuclear cell (BMNC) samples from 3 MM patients were thawed from frozen stocks. BMNC samples were surplus material from bone marrow isolated for diagnostic procedures. All patients approved use of surplus material for scientific purposes by informed consent. Use of surplus material has been discussed with and approved by the review board of the University Medical Center Utrecht. The samples were first suspended in fresh RPMI medium and kept in an incubator for a few hours. Cellular debris were removed by using Ficoll hypaque centrifugation, and rest of the samples were cultured overnight in RPMI medium supplemented with 10% fetal bovine serum, 100U/ml penicillin and 100 μg/ml streptomycin in a 37°C incubator with 5% CO2.

Reverse Transcriptase-polymerase Chain Reaction

Total RNA was extracted from the cells by RNeasyMinikit (Qiagen, Valencia, CA, USA) following manufacturer’s instructions. For cDNA first strand synthesis, 2.5 μg of total RNA was reverse transcribed using SuperScript™ reverse transcriptase. The primer sequences used for TLR 1, 2, 4, 5, 7, 8 were described before [12].

Other primer sequences obtained from Isogen (De Meern, the Netherlands) were as follows: TLR3-forward: 5’TGCGGTCTATTGTGCCACACACT-3’, TLR3-reverse: 5’CAGGTCGTGCAGTCGCAA-3’, TLR9-forward: 5’TCAGACTGTGCGTCTGCGGCTG-3’, TLR9-reverse: 5’AGGCCGCCATTTGGACAGATGC-3’, beta-actin primers had also been already described [18]. To perform the reactions in a total volume of 25 μl, we used the following conditions: primary denaturation at 95°C for 3 minutes, 35 cycles
of 30 sec at 94°C, 40 sec at 58°C, 40 sec at 72°C, and 10 minutes at 72°C.

Quantitative Real Time Polymerase Chain Reaction

Quantitative PCR was performed for the expression of TLR3 mRNA in Fravel, L363 and NCI- H929. 500 ng total RNA from indicated cell lines was transcribed using a first strand synthesis kit (Qiagen). Two microliters from each sample was applied to SYBR green real time PCR using primers which were as described previously [19]. The beta actin primer was described above. Standard curves for targets and beta actin genes were created with two-fold dilutions of a measured concentration of pooled cDNA. The amount of amplicon for each gene (TLR3 and TLR5) in samples was then determined using log of concentration and slope of the curve and normalized to that of actin. We used a two-step PCR protocol with the following temperature profile: 5 min 95°C, 40 cycles of (15 sec 95°C, 30 sec 58 or 65°C), including a melting curve at the end.

Western Blotting

Five to ten million cells from each cell line were harvested, washed in cold PBS and suspended in lysis buffer (150 mM NaCl, 1% IGEPAL (Sigma), 50 mM Tris, pH 8.0) followed by addition of protease inhibitor cocktail (Complete Mini pills, Roche). The lysates were then left on ice for 30 minutes, spun at 10,000×g for 10 minutes and supernatants were isolated. The protein concentration of lysates was determined with a BCA kit (Pierce) and 30 μg total protein from each lysate was electrophoresed on an 8 or 12% SDS-PAGE gel and subsequently electro blotted onto a PVDF membrane. The membranes were incubated with primary antibodies (1–3 μg) overnight at 4°C followed by incubation with HRP-conjugated secondary antibodies (1:2000–1:5000). The signals were detected by using ECL PLUS or ECL Prime (Amersham). Membranes were reprobed for a maximal of 3 times with different TLR antibodies and anti-beta-actin, after stripping the membranes with Restore Western Blot Stripping buffer (Pierce).

Figure 2. Expression analysis of TLR protein in HMCLs by Western blotting. All cell lines displayed a strong expression of TLR1, TLR3, TLR4, TLR7, TLR8, TLR9 proteins. Cell lysates were electrophoresed and blotted to PVDF membrane, which was probed with TLR-specific antibodies. To confirm the immunoreactivity of the antibodies, different positive controls were included. Beta-actin was served as loading control and was used to normalize expression levels between cells (see Figure 5). Data are representative for analysis of ≥2 independent experiments.

doi:10.1371/journal.pone.0060671.g002

Figure 3. Expression analysis of TLR4 and TLR8 protein in HMCLs by Western blotting. Lysates of human intestinal tissue (A) and mouse splenocytes (B) were used as positive controls. Beta-actin was served as loading control and was used to normalize expression levels between cells (see Figure 5). Data are representative for analysis of ≥2 independent experiments.

doi:10.1371/journal.pone.0060671.g003
In FACS experiments, indirect (intra)cellular staining was performed using TLR-specific antibodies. Briefly, $10^5$ cells from each cell line or BMNCs were harvested and washed in FACS buffer, PBS + 0.5% BSA + 0.01% sodium azide, pelleted and suspended in permeabilization/fixation buffer (from eBioscience), and left for 20 minutes at room temperature. The cells were then washed in permeabilization buffer, pelleted and incubated with 1–2 mg of indicated primary antibody at room temperature (or 4°C) for one hour. FITC-conjugated secondary antibodies, anti-rabbit IgG and anti-mouse IgG, were added at the next step. Finally, the samples were washed, suspended in FACS buffer and then analyzed using a FACSCanto™ II flow cytometer (BD Biosciences) for TLR detection, and captured data of gated live populations were analyzed using CellQuest software. Human peripheral blood mononuclear cells (PBMCs) isolated from buffy coat (Sanquin, the Netherlands) were used as positive control in some experiments. Patient BMNCs were washed and stained with APC-conjugated anti-human CD138 in FACS buffer followed by staining with TLR-specific antibodies containing as described above. FACS analysis for TLR expression was performed on live gated CD138-positive cells.

**Results**

**Analysis of TLR mRNA Expression in HMCLs**

Expression of mRNA for TLR1, TLR3, TLR4, TLR7, TLR8, and TLR9 was found in all myeloma cell, but levels of mRNA expression differed amongst different cell lines (Fig. 1). TLR2 mRNA was not detected in Fravel and L363. Expression of TLR3 mRNA was also analyzed using qPCR in 3 cell lines: Fravel, L363, and NCI-H929. The TLR3/actin expression of Fravel, L363, and NCI-H929 was 0.083, 0.043 and 0.086, respectively. Absolute quantities of TLR3 amplicon were 4.84 ± 1.82 ng, 1.35 ± 0.66 ng and 4.81 ± 1.8, respectively.

**Analysis of TLR Protein Expression in HMCLs using Western Blot**

In all cell lines, expression of TLR1, TLR3, TLR4, TLR7, TLR8, and TLR9 was detected using immunoblotting (Figs 2,3).

---

**Figure 4.** HCML do not express of TLR2 and TLR5. Expression of TLR2 and 5 at protein level was determined by western blotting (panel A and B) and FACS (panel C). The immunoreactivity of the anti-TLR2 and -5 antibodies in western blotting and FACS analysis was confirmed with human intestinal lysate (panel A and B) and human PMBCs as positive controls (panel C), respectively. Data are representative for analysis of ≈2 independent experiments. doi:10.1371/journal.pone.0060671.g004
On the other hand, TLR2 and TLR5 proteins were not found in any of cell lines. The absence of signal was not due to a lack of reactivity of the antibodies used, because strong expression of these TLRs was found in human intestine tissue lysate (Fig. 4). Furthermore, using densitometry the ratio of TLR protein densities to those of beta actin was determined and showed that relative expression levels of TLRs varied amongst different cell lines (Fig. 5). For example, in TLR4 group, a prominent difference in relative protein level is obvious between RPMI 8226, Fravel and U266 cell lines. In the TLR8 group, L363 displays the highest level of the protein, and in TLR1, TLR3, TLR7, TLR9 groups the highest level of the relevant proteins is seen in the NCI-H929 cell line.

Analysis of TLR Expression using Flow Cytometry
In the next experiments, the expression of TLR protein was analyzed by flow cytometry. TLR1, TLR7, TLR8, TLR9 were strongly expressed by HMCLs (Figs 6 and 7). In agreement with the Western blotting analysis, TLR2 and TLR3 were found not expressed by any of HMCLs in FACS analysis. In control experiments, we confirmed that antibodies used were able to detect TLR2 and TLR5 expression in human peripheral blood mononuclear cells (Fig. 4). Interestingly, expression of TLR-3 and TLR-4 in some cell lines (Fravel and NCI-H929) was very low, while the bands of these proteins in immunoblotting analysis were prominent, probably suggesting posttranslational modifications.
For primary MM cells, in BMNCs, live CD138-positive cells were gated and the percentage of cells binding to TLR-specific antibodies was calculated (Fig. 8). CD138<sup>+</sup>-BMNCs displayed a strong expression of TLR1, TLR7, TLR8 and TLR9. Some variation in the expression of TLR8 and TLR9 was found in samples of different patients. The percentage of TLR9 positive cells in MM1, MM2 and MM3 was 47.2, 97.8, and 53, respectively, while 16.7%, 52.7% and 20.8% of cells were positive for TLR8 in these patients.

**Discussion**

The expression of TLRs on cells of B-lymphoid malignancies, MM and CLL, has been documented in different recent studies [10,12–15,20]. These studies, however, show inconsistencies in TLR patterns expressed by MM cells and the cellular responses following their triggering. This is the first study in which TLR expression in different HMCLs and primary MM cells has been evaluated at mRNA (RT-PCR) and protein (Western blot and flow cytometric analysis) level (Table 1). All analyzed HMCLs express mRNA for TLR1, TLR3, TLR4, TLR5, TLR7, TLR8, and TLR9. Although RT-PCR analysis is not a quantitative method, analysis of TLR3 expression in some HMCLs with real-time PCR provided a comparable expression profile. The pattern of TLR1, TLR2, TLR7, and TLR9 mRNA expression for NCI-H929, XG1, RPMI 8226, and L363 is in agreement with that described by Jego et al [12]. However, our results show differences with those obtained by Bohnhorst et al for OPM2, RPMI 8226, NCI-H929 and U266 cell lines [14]. While the pattern of TLR1, TLR2, TLR5, TLR9 mRNA expression is the same as in our cell lines, no mRNA for TLR3, TLR7, TLR8 in OPM-2, and TLR4, TLR7 in U266 cells was found in their study [14].

Analysis of TLR expression at protein level showed that TLR1, TLR3, TLR4, TLR7, TLR8, and TLR9, were expressed in most HCMLs. TLR analysis using western blotting closely correlated with the expression pattern found by flow cytometric analysis. Comparison of TLR expression at transcriptional and translation level showed discrepancies between presence of TLR mRNA and protein. For example, some cell lines expressed very low levels of TLR3 mRNA (e.g. Fravel, L363, and U266), while TLR3 protein was clearly expressed. On the other hand, presence of mRNA did not predict the expression of functional protein for some TLRs. Most notably was the marked presence of TLR5 mRNA in all HMCLs, while no expression of TLR5 at protein level was detected. This discordant relation between mRNA and protein expression may be caused by a low stability of the specific mRNA and translation and post-translational modifications of the specific protein. Similarly, Arvaniti et al. found that some B-CLL cells do not express TLR6 protein in spite of a high mRNA level, and also

**Figure 6. Expression of TLRs in Fravel, L363, OPM1, RPMI8226, XG1, and NCI-H929 as determined by flow cytometry.** HCMLs were stained using an intracellular staining protocol with TLR-specific antibodies followed by relevant secondary fluorescent-conjugated antibodies. TLR2 and TLR5 proteins were not detectable in any of cell lines. Filled histograms (purple) represent the isotype controls and the open histograms (red) indicate specific antibodies. Data are representative for analysis of ≥2 independent experiments.

doi:10.1371/journal.pone.0060671.g006
Figure 7. Expression of TLRs in UM6, UM9, U266, and OPM2 as determined by flow cytometry. HMCLs were stained using an intracellular staining protocol with TLR-specific antibodies followed by relevant secondary fluorescent-conjugated antibodies. TLR2 and TLR5 were not expressed by any of cell lines, confirmed also by using positive controls (see Fig. 4). Filled histograms (purple) represent the isotype controls and the open histograms (red) indicate TLR-specific antibodies. Data are representative for analysis of ≥2 independent experiments.

doi:10.1371/journal.pone.0060671.g007

Figure 8. TLR protein expression pattern in primary BMNCs from 3 MM patients analyzed by flow cytometry. CD138-positive cells were gated from the total cell population. Staining with specific antibodies for TLR1, TLR2, TLR3, TLR5, TLR7, TLR8, and TLR9 was compared with isotype-matched controls (NC).

doi:10.1371/journal.pone.0060671.g008
most samples display a high expression of proteins for TLR2 and TLR8 in spite of a low mRNA [21].

Expression of TLR1, TLR7, TLR8, and TLR9 in primary cells from MM patients was comparable with the profile in HMCLs, although some variation between patients was found in the extent of TLR8 and TLR9 expression. Primary MM cells showed a lower level of TLR2, TLR3 and TLR5 expression as compared to normal B cells [19]. This may also suggest that the origin of the tissue may have determined the TLR expression pattern. Of note, mRNA for TLR3, TLR4, and TLR8 was not detected in B cells of B-CLL patients [23], implying that MM cells originate from B cells of patients. However, mRNA for TLR4 was found in B cells of B-CLL patients [23], implying that MM cells may differently regulate the expression of specific TLRs.

Primary MM cells showed a low level of TLR2, TLR3 and TLR5 expression as compared to HMCCLs, while in all 10 HMCLs a strong signal for TLR-3 but no expression of TLR2 and TLR5 was found. Such heterogeneity in HMCLs, while in all 10 HMCLs a strong signal for TLR-3 but no expression of TLR2 and TLR5 was found. Such heterogeneity in HMCLs, while in all 10 HMCLs a strong signal for TLR-3 but no expression of TLR2 and TLR5 was found.

Taken together, our expression analyses indicate that HMCLs display a broad range of TLRs at gene and protein levels. This study also shows that analysis of mRNA alone may not provide a correct prediction of functional TLR protein expression in HMCLs [24]. Indeed, strong expression of TLRs in HMCLs and primary tumor cells indicates a propensity for responding to tumor-induced inflammatory signals which seem inevitable in MM bone marrow environment. TLR triggering on HMCL and MM primary cells has been associated with heterogeneous effects including increase in proliferation, survival, cytokine and chemokine production, induction of apoptosis or protection from apoptosis, drug-resistance and immune escape [11]. Our study suggests that effects on tumor cells through stimulation of TLRs by endogenous ligands such as soluble syndecan-1, matrix metalloproteinase products, heat-shock proteins, HMGB-1, which are released due to cell necrosis, should also be considered in MM [25].

Author Contributions
Conceived and designed the experiments: JA TM JG FR. Performed the experiments: JA. Analyzed the data: JA TM FR. Contributed reagents/materials/analysis tools: TM. Wrote the paper: JA FR.

References
1. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7: 585–598.
2. Pratt G, Goodyear O, Moss P (2007) Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 138: 563–579.
3. Paradisi F, Corti G, Cinelli R (2001) Infections in multiple myeloma. Infect Dis Clin North Am 15: 373–384, vii-viii.
4. Prabhala RH, Neri P, Bar JE, Tassone P, Shammas MA, et al. (2006) Dysfunctional T regulatory cells in multiple myeloma. Blood 107: 301–304.
5. Brown LM, Gridley G, Check D, Landgren O (2008) Risk of multiple myeloma and monoclonal gamopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 111: 3388–3394.
6. Chen R, Alvero AB, Silasi DA, Mor G (2007) Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. Am J Reprod Immunol 57: 93–107.
7. Rakoff-Nahoum S, Medzhitov R (2009) Toll-like receptors and cancer. Nat Rev Cancer 9: 57–63.
8. Chen R, Alvero AB, Silasi DA, Steffensen KD, Mor G (2008) Cancers take their toll—the function and regulation of Toll-like receptors in cancer cells. Oncogene 27: 225–233.
9. Chen K, Huang J, Gong W, Iribarren P, Dunlop NM, et al. (2007) Toll-like receptors in inflammatory, infection and cancer. Int Immunopharmacol 7: 1271–1285.
10. Chiron D, Bekerfijian-Ding I, Pellat-Dezeunyck C, Bataille R, Jego G (2008) Toll-like receptors: lessons to learn from normal and malignant human B cells. Blood 112: 2205–2213.
Abdi J, Engel F, Garsen J, Redegeld F (2011) The role of toll-like receptor mediated signalling in the pathogenesis of multiple myeloma. Crit Rev Oncol Hematol 80: 225–240.

Jego G, Bataille R, Geoffroy-Laeuse A, Descamps G, Pellat-Deceunynck C (2006) Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 20: 1130–1137.

Chiron D, Pellat-Deceunynck C, Amiot M, Bataille R, Jego G (2009) TLR3 ligand induces NF-κB activation and various fates of multiple myeloma cells depending on IFN-α production. J Immunol 182: 4471–4478.

Bohnhorst J, Rausenm C, Meen SH, Flottem M, Knudsen L, et al. (2006) Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia 20: 1130–1144.

Xu Y, Zhao Y, Huang H, Chen G, Wu X, et al. (2010) Expression and function of toll-like receptors in multiple myeloma patients: toll-like receptor ligands promote multiple myeloma cell growth and survival via activation of nuclear factor-kappaB. Br J Haematol 150: 543–553.

van de Donk NW, Kamphuis MM, Lokhorst HM, Bloem AC (2002) The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 16: 1362–1371.

van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, et al. (2011) Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 96: 284–290.

Wang S, Hong S, Yang J, Qian J, Zhang X, et al. (2006) Optimizing immunotherapy in multiple myeloma: Restoring the function of patients’ monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells. Blood 108: 4071–4077.

Dorner M, Brandt S, Tinguely M, Zucol F, Bourquin JP, et al. (2009) Plasma cell toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production. Immunology 128: 573–579.

Bourke E, Bosissio D, Golay J, Polentarutti N, Mantovani A (2005) The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood 102: 956–963.

Arvaniti F, Ntoufia S, Papaconstantinou X, Touloumenidou T, Laoutarit N, et al. (2011) Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients. Haematologica 96: 1644–1652.

Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, et al. (2007) Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 110: 296–304.

Rekowska D, Novotna L, Pylit R, Hochova I, Kozak T, et al. (2010) Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation. Int J Cancer 126: 1132–1143.

Guo Y, Xiao P, Lei S, Deng F, Xiao GG, et al. (2008) How is mRNA expression predictive for protein expression? A correlation study on human circulating monocytes. Acta Biochim Biophys Sin (Shanghai) 40: 426–436.

Jeannin P, Jaillon S, Delneste Y (2008) Pattern recognition receptors in the immune response against dying cells. Curr Opin Immunol 20: 530–537.